Garenoxacin pharmacokinetics in subjects with renal impairment^*

References

• Boswell FJ, Andrews JM, Wise R. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001;48: 446–7
   Google Scholar
• Fix AM, Pfaller MA, Biedenbach DJ, et al. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Int J Antimicrob Agents 2001;18:141–5
   PubMed Web of Science ®Google Scholar
• Hoellman DB, Kelly LM, Jacobs MR, et al. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001;45:589–92
   PubMed Web of Science ®Google Scholar
• Malay S, Roblin PM, Reznik T, et al. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2002;46:517–8
   PubMed Web of Science ®Google Scholar
• Takahata M, Shimakura M, Hori R, et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001;45:312–5
   PubMed Web of Science ®Google Scholar
• Takahata M, Mitsuyama J, Yamashiro Y, et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999;43:1077–84
   PubMed Web of Science ®Google Scholar
• Bassetti M, Dembry LM, Farrel PA, et al. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob Agents Chemother 2002;46:234–8
   PubMed Web of Science ®Google Scholar
• Schmitz FJ, Milatovic D, Boos M, et al. In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. J Antimicrob Chemother 2002;49:698–700
   PubMed Web of Science ®Google Scholar
• Bello A, Stewart C, O’Mara E, et al. Absolute oral bioavailability of garenoxacin tablets and the bioequivalence of the intravenous formulation with respect to oral tablets. 37th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting; December 8–12, Atlanta, GA, 2002
   Google Scholar
• Gajjar DA, Bello A, Ge Z, et al. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003;47:2256–63
   PubMed Web of Science ®Google Scholar
• Andrews J, Honeybourne D, Jevons G, et al. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 2003;51: 727–30
   PubMed Web of Science ®Google Scholar
• Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766–77
   PubMed Web of Science ®Google Scholar
• Stewart C, Gajjar D, Bello A, et al. Safety, tolerability and pharmacokinetics of BMS-284756, a novel des-F(6)-quinolone, following 28 days of once daily oral dosing in healthy subjects. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22–25, Chicago, IL, 2001
   Google Scholar
• Toussaint B, Chedin M, Bordin G, et al. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography–tandem mass spectrometry. I. Laboratory-validated method. J Chromatogr A 2005;1088:32–9
   PubMed Web of Science ®Google Scholar
• Toussaint B, Chedin M, Vincent U, et al. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography–tandem mass spectrometry. Part II: intercomparison exercise. J Chromatogr A 2005;1088:40–8
   PubMed Web of Science ®Google Scholar
• Hayakawa H, Fukushima Y, Kato H, et al. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab Dispos 2003;31:1409–18
   PubMed Web of Science ®Google Scholar
• Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002;53:232–7
   PubMed Web of Science ®Google Scholar
• Plaisance KI, Drusano GL, Forrest A, et al. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1990;34:1031–4
   PubMed Web of Science ®Google Scholar
• Fillastre JP, Montay G, Bruno R, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother 1994;38:733–7
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Koup JR, Rausch G, et al. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function. Antimicrob Agents Chemother 2001;45:2536–42
   PubMed Web of Science ®Google Scholar
• Granneman GR, Braeckman R, Kraut J, et al. Temafloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother 1991;35: 2345–51
   PubMed Web of Science ®Google Scholar
• Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600–3
   PubMed Web of Science ®Google Scholar
• Bello A, Hollenbaugh D, Gajjar D, et al. Ex vivo protein binding of BMS-284756: impact on the unbound AUC/MIC ratio for Streptococcus pneumoniae. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22–25, Chicago, IL, 2001
   Google Scholar